General
Preferred name
ICOSAPENT ETHYL
Synonyms
OMEGA-3-ACID ESTERS (EPA shown) ()
EPA ethyl ester ()
Ethyl eicosapentaenoate ()
ETHYL ICOSAPENTATE ()
Eicosapentaenoic Acid ethyl ester ()
AMR101 ()
AMR101, EPA ethyl ester, Ethyl eicosapentaenoate ()
all cis-5,8,11,14,17-Eicosapentaenoic Acid Ethyl Ester ()
Eicosapentaenoic Acid ethyl ester-d5 ()
icosapent ()
AMR 101 ()
AMR-101 ()
Icosapent ethyl ester ()
Vascepa ()
Timnodonic acid ethyl ester ()
Epadel ()
NSC-759597 ()
Eicosapentaenoic acid ethyl ester ()
Vazkepa ()
Ethyl icosapent ()
Eicosapentaenoic Acid-d5 ethyl ester ()
P&D ID
PD002529
CAS
86227-47-6
73310-10-8
2483831-19-0
Tags
available
prodrug
drug
Approved by
FDA
PMDA
EMA
First approval
2012
Drug Status
approved
investigational
nutraceutical
Max Phase
4.0
Drug indication
Cardiovascular disease
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Icosapent is a synthetic ethyl ester derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA). It is de-esterified during absorption to active EPA that is absorbed in the small intestine.
(GtoPdb)
DESCRIPTION
Eicosapentaenoic acid ethyl ester (EPA ethyl ester) is an orally active ¦Ø-3 fatty acid agent. Eicosapentaenoic acid ethyl ester could improve the activity of liver ¦Â-oxidase in vitro, reduce the level of liver total triglyceride, increase the content of liver triglyceride and phospholipid ¦Ø-3 fatty acid, and increase the total ¦Ø-3 fatty acid level in rats[1][2][3].
PRICE
29
DESCRIPTION
all cis-5,8,11,14,17-Eicosapentaenoic Acid Ethyl Ester is an omega-3 fatty acid agent. It is important polyunsaturated fatty acid of the marine food chain. It serves as a precursor of the prostaglandin-3 and thromboxane-3 families. It differs from arachidonic acid by the extra double bond between the third and fourth carbons from the "methyl end" of the molecule. It reduces non-high-density lipoprotein cholesterol, lipoprotein-associated phospholipase A2, apolipoprotein B, very low-density lipoprotein cholesterol, and total cholesterol. It reduces the TG levels and improved other lipid parameters without significantly increasing the LDL cholesterol levels. It is used in combination with changes in diet to lower triglyceride levels in adults with severe (≥ 500 mg/dL) hypertriglyceridemia. It has anti-inflammatory and cardiovascular benefits. It may alter the expression of genes related to fatty acid metabolism. It was the second class of fish oil-based drug to be approved for use as a drug. It was developed by Amarin Corporation. It has been listed.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Eicosapentaenoic acid ethyl ester (Ethyl eicosapentaenoate) is an omega-3 fatty acid.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
15
BOC Sciences Bioactive Compounds
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
Guide to Pharmacology
MedChem Express Bioactive Compound Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
43
Molecular Weight
330.26
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
0
Rotatable Bonds
14
Ring Count
0
Aromatic Ring Count
0
cLogP
6.47
TPSA
26.3
Fraction CSP3
0.5
Chiral centers
0.0
Largest ring
0.0
QED
0.21
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Endogenous Metabolite
Fatty acid synthase
MOA
cholesterol inhibitor
Pathway
Metabolism
Metabolic Enzyme/Protease
Solubility
10 mM in DMSO
Source data
